ArticleMolecular biology reports2025
Effects of nerolidol on serum cytokines in acute myocardial infarction: insights into the asprosin, spexin, and DARS2 antibodies in the brain cortex.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Emerging roles of spexin in cardiovascular homeostasis.Frontiers in cardiovascular medicine · 2026Review
- Serum asprosin levels as a potential prognostic biomarker in COVID-19: insights for future respiratory viral pandemics.BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOxidative stress and inflammation are pivotal in pathogenesis of brain ischemia-reperfusion (I/R) injury. This study evaluated neuroprotective effects of nerolidol (NRD) on asprosin (ASP), spexin (SPX), and DARS2 expressions in myocardial infarction (MI) induced cerebral I/R injury, and systemic inflammatory responses by measuring serum cytokine levels. METHODS AND
resultsTwenty-eight Wistar rats were divided into: Control, MI (200 mg/kg isoproterenol), NRD (100 mg/kg/day), and MI + NRD groups. After 14 days, brain cortex tissues were analyzed histopathologically and immunohistochemically, while serum TAS, TOS, and cytokines were measured via ELISA. Histopathological examination revealed severe cortical damage in MI rats, which was significantly attenuated by NRD treatment. Immunohistochemistry showed marked upregulation of ASP, SPX, and DARS2 in the MI group, with NRD normalizing SPX/DARS2 and partially reducing ASP. Serum analysis revealed comprehensive therapeutic effects of NRD, effectively counteracting the metabolic and inflammatory disturbances caused by MI. The treatment completely restored depleted Metrnl levels to normal values, demonstrating its metabolic regulatory capacity. NRD also showed potent anti-inflammatory action, significantly lowering elevated levels of key pro-inflammatory cytokines while maintaining a balanced immune response. Furthermore, it effectively corrected the oxidative imbalance characteristic of I/R injury, normalizing both oxidant and antioxidant markers to near-control levels. NRD effectively reduces cerebral I/R injury after MI by combining antioxidant, anti-inflammatory, and metabolic regulatory actions. It normalizes Metrnl, cytokines, and oxidative stress markers while modulating ASP/SPX/DARS2 pathways, suggesting their role in both injury and recovery.
conclusionsThese findings highlight the potential of NRD in preventing post-MI brain damage and the need for further research on optimal dosing and mechanistic pathways.
Indexed as
Identifiers
40679581What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.